Biliary tract cancers: SEOM clinical guidelines

M. Benavides ^[5] ; A. Antón ^[1] ; J. Gallego ^[6] ; M. A. Gómez ^[2] ; A. Jiménez-Gordo ^[7] ; A. La Casta ^[3] ; B. Laquente ^[4] ; T. Macarulla ^[8] ; J. R. Rodríguez-Mowbray ^[9] ; J. Maurel ^[10]
1. [1] Hospital Miguel Servet
  
  Hospital Miguel Servet
  
  Zaragoza, España
2. [2] Hospital Universitario Reina Sofia
  
  Hospital Universitario Reina Sofia
  
  Cordoba, España
3. [3] Hospital Universitario de Donostia
  
  Hospital Universitario de Donostia
  
  San Sebastián, España
4. [4] Institute Catalá Oncología
  
  Institute Catalá Oncología
  
  Barcelona, España
5. [5] Hospital Universitario Regional y Virgen de la Victoria
6. [6] Hospital General Universitario, Elche
7. [7] Hospital Universitario Infanta Sofía
8. [8] Hospital Universitario Vall d’Hebron
9. [9] Hospital Infanta Cristina
10. [10] Hospital Clínic
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 982-987
Idioma: inglés
Texto completo no disponible (Saber más ...)

Resumen
- Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to improve survival and quality of life of this disease.